ESGCT 2022: The New Normal for the Gene Therapy Community

Human Gene TherapyVol. 33, No. 17-18 EditorialESGCT 2022: The New Normal for the Gene Therapy CommunityTerence R. FlotteTerence R. Flotte*Correspondence: E-mail Address: [email protected]Editor-in-Chief, Human Gene Therapy, Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, New York, USA.Search for more papers by this authorPublished Online:16 Sep 2022https://doi.org/10.1089/hum.2022.29217.editorialAboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View article"ESGCT 2022: The New Normal for the Gene Therapy Community." Human Gene Therapy, 33(17-18), p. 841FiguresReferencesRelatedDetails Volume 33Issue 17-18Sep 2022 InformationCopyright 2022, by Mary Ann Liebert, Inc., publishersTo cite this article:Terence R. Flotte.ESGCT 2022: The New Normal for the Gene Therapy Community.Human Gene Therapy.Sep 2022.841-841.http://doi.org/10.1089/hum.2022.29217.editorialPublished in Volume: 33 Issue 17-18: September 16, 2022PDF download